Altogether! : industrials, academics, patients associations, and regulator agree to enlarge the inclusion criteria in clinical trials aiming to test new drugs indicated in Alzheimer disease.
The goal is to evaluate bio engineering issued medicine called “bapineuzumab” in 2012 and 2013.
Bio engineering drugs are among the most expansive drugs because they are issued from genetically modified cells. All their names end with the acronym “umab” which means Human Anti Body.